New York, NY -- (SBWIRE) -- 01/28/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Cleveland BioLabs, Inc (NASDAQ:CBLI), Pacific Biosciences of California (NASDAQ:PACB), Extreme Networks, Inc (NASDAQ:EXTR), Spherix Inc (NASDAQ:SPEX)
Cleveland BioLabs, Inc (NASDAQ:CBLI) showed a volume of 1.39 million shares by the end of last trade whereas the average volume of the stock remained 512,172.00 shares. The stock opened the session at $0.74 but then moved to $0.680. At that price, the stock showed a negative performance of -1.43%. Cleveland BioLabs, Inc. is a clinical-stage biotechnology company with a focus on oncology drug development. The Company’s lead drug candidate CBLB502 is developed for dual indications under the United States Food & Drug Administration's (FDA's) Animal Efficacy Rule,
Will CBLI Get Buyers Even After The Recent Rally? Find Out Here
Pacific Biosciences of California (NASDAQ:PACB) opened the session at $7.24 and closed the session at $7.25. The stock showed a positive performance of -3.72% in previous trading session. Traded with volume of 1.37 million shares in the prior session and the average volume of the stock remained 997,886.00 shares. Pacific Biosciences, Inc. develops Deoxyribonucleic Acid (DNA) sequencing platform. The Company designs and develops a method for single-molecule DNA sequencing that was developed through collaboration between the research groups of Harold Craighead and Watt Webb at Cornell University, United States.
For How Long PACB will fight for Profitability? Read This Trend Analysis report
Extreme Networks, Inc (NASDAQ:EXTR) opened the session at $7.40 and closed the session at $7.24. The stock showed a negative performance of -1.50% in previous trading session. Traded with volume of 1.36 million shares in the prior session and the average volume of the stock remained 1.19 million shares. The beta of the stock remained 1.67. Extreme Networks, Inc. together with its subsidiaries, is a provider of network infrastructure equipment and services for enterprises, data centers, and service providers. The Company’s customers include businesses, hospitals, schools, hotels, telecommunications companies and government agencies globally.
Why Should Investors Buy EXTR After the Recent Fall? Just Go Here and Find Out
Spherix Inc (NASDAQ:SPEX) the stock decreased -29.28% and finished the session at $5.83. Traded with volume of 1.35 million shares in the prior session and the average volume of the stock remained 79,029.00 shares. The beta of the stock remained 0.47. Spherix Incorporated (Spherix) is a scientific research company. The Company is engaged in developing biopharmaceutical products and providing technical and regulatory consulting services to food, consumer products and pharmaceutical companies.
Will SPEX Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)